This is the English translation of a Japanese press release published on August 5, 2025. If there are any differences in content or interpretation, the Japanese version shall prevail.

August 5, 2025

Notification Regarding Status of Acquisition of Treasury Shares

(Acquisition of the company's own shares under the regulations of the Articles of Incorporation pursuant to Article 165, paragraph (2) of the Companies Act)

Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide) is pleased to announce the current status of the acquisition of its own shares pursuant to Article 156 of the Companies Act of Japan (the Companies Act), as applied under Article 165, paragraph (3) of the Companies Act, as previously announced on July 10, 2025. The details are as follows:

1.	Type of shares acquired	Common share of Hisamitsu Pharmaceutical
2.	Total number of shares acquired	1,765,400 shares
3.	Total amount of acquisition cost	7,109,265,800 yen
4.	Period for acquisition	From July 11, 2025 to July 31, 2025
		(based on contract)
5.	Method of acquisition	Purchase through an off-auction own share
		repurchase transaction (ToSTNeT-3) on Tokyo
		Stock Exchange

(Reference)

1. Details of Resolution of the board of directors meeting held on July 10, 2025

(1)	Type of shares to be acquired	Common share of Hisamitsu Pharmaceutical
(2)	Total number of shares to be	3 million shares (Maximum)
	acquired	4.09% of total number of outstanding shares
		[excluding treasury shares]
(3)	Total amount of acquisition cost	15 billion yen(Maximum)
(4)	Period for acquisition	From July 11, 2025, to December 31, 2025
(5)	Method of acquisition	(i) Acquire through an off-auction own share repurchase transaction (ToSTNeT-3)(ii) Acquire in the open market through discretionary trading on the Tokyo Stock Exchange

- 2. Cumulative total of treasury shares acquired based on the above resolutions of the board of directors meeting (as of July 31, 2025)
- (1) Total number of shares acquired 1,765,400 shares
- (2) Total amount of acquisition cost 7,109,265,800 yen